EXEL Stock Analysis: Buy, Sell, or Hold?
EXEL - Exelixis Inc
$51.57
0.22 (0.43%)
▲
5d:
-2.7%
30d:
+3.87%
90d:
+24.54%
BUY
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Jul 27, 2026
Get Alerted When EXEL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: EXEL shows positive signals but monitor for confirmation. Market pricing in 1.6% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: EXEL shows positive signals but monitor for confirmation. Market pricing in 1.6% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$74.16
Based on 8.7% avg growth
INTRINSIC VALUE TODAY
$46.05
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EXEL is currently trading at $51.57, which is considered fair relative to its 30-day fair value range of $49.84 to $52.63. The stock's valuation (Forward PE: 12.7) is in line with its historical norms (12.1). At these levels, the market is pricing in 1.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, EXEL is in a strong uptrend. The price is currently testing key support at $50.80. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EXEL is in a strong uptrend. The price is currently testing key support at $50.80. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$49.84 -
$52.63
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
68.6%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($49.00)
- NEUTRAL: Market pricing in 1.6% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$49.84 -
$52.63
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$50.80
Resistance Level
$53.93
Current Trend
Strong Uptrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.68
Wall Street Target
$49.00
(-4.6%)
Revenue Growth (YoY)
10.0%
Earnings Growth (YoY)
43.6%
Profit Margin
35.1%
Valuation Premium vs History
+1.6% premium
PE vs Historical
12.7 vs 12.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.6%
(market-implied from PE analysis)
1-Year Target
$52.17
(+2%)
2-Year Target
$53.01
(+3%)
3-Year Target
$53.85
(+5%)
3-Yr Target (if PE normalizes)
(PE: 13→12)
PE COMPRESSION
$51.37
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 13.4%)
$128.66
(+151%)
Base:
(SPY PE: 12.7, Growth: 13.4%)
$74.93
(+46%)
Bear:
(PE: 10.8, Growth: 13.4%)
$63.69
(+24%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (17x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 17.19 | Current EPS (TTM): $3.02
Bull Case
$76.54
(+49%)
Analyst growth 34.0%, PE expands to 18.9
Base Case
$69.58
(+36%)
Market implied 34.0%, PE stable at 17.2
Bear Case
$35.30
(-31%)
Severe decline -20.0%, PE contracts to 14.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 23, 2026 12:56 PM ET
Data refreshes hourly during market hours. Next update: 1:56 PM
Data refreshes hourly during market hours. Next update: 1:56 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EXEL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Dana Aftab
SELL
47918 shares
2026-02-24
Dana Aftab
SELL
29873 shares
2026-02-19
Brenda Hefti
SELL
18669 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 64 BUY |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 59 HOLD |
Advanced EXEL Option Strategies
Professional options setups generated by AI based on today's EXEL price and gamma walls.
